Abbott's Cancerguard is a multi-cancer early detection test built by Exact Sciences, the company Abbott bought for about $21 billion in a deal that closed on March 23, 2026.
A single blood draw is used to screen for more than 50 cancer types and subtypes.
In studies of more than 20,000 participants, the test flagged 68 percent of six of the deadliest cancers, including lung, pancreatic, liver and ovarian.
Specificity was 97.4 percent, so fewer than 3 in 100 people without cancer received a false-positive result.
Also read: What inflammation is doing to your mood, and what it could mean for depression
The test looks for two kinds of biomarkers in one blood sample. It reads patterns of DNA methylation, chemical tags on tumor DNA that leak into the bloodstream, alongside a panel of cancer-linked proteins.
New data presented at the American Association for Cancer Research meeting in April 2026 showed the dual approach matters. About 47 percent of positive signals came from methylation alone, 7 percent from protein alone and 45 percent from both.
Who qualifies and what it costs
Cancerguard is a prescription test for adults aged 50 to 84 with no cancer diagnosis in the past three years. It launched on September 10, 2025 at $689 out of pocket.
Insurance does not currently cover the test, though the company says it is pursuing coverage. Blood can be drawn at about 7,000 Quest Diagnostics locations or through mobile phlebotomy after ordering through the Cancerguard telehealth portal.
Also read: Your blood pressure reading at the doctor's office may not reflect your real numbers
The FDA status of the test
Cancerguard is a laboratory-developed test. It has not been cleared or approved by the U.S. Food and Drug Administration.
Exact Sciences is enrolling a registry of 25,000 participants under an FDA Investigational Device Exemption to build the evidence needed for a future FDA submission.
What a positive result actually means
A positive result does not confirm cancer. It is a signal that something suspicious has been detected, and follow-up imaging is needed to locate a possible tumor.
Because the test targets more than 50 cancer types, including many with no recommended screening today, it is designed to complement standard screens such as mammography and colonoscopy, not replace them.
Also read: A one-time cell therapy left half of severe rheumatoid arthritis patients drug-free
Anyone considering Cancerguard should talk with their doctor first about how a positive or negative result would fit into their overall screening plan.
Also read: These habits can leave you feeling stuck and exhausted
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.